



Co-funded by  
the European Union



MINISTRY OF INDUSTRY AND TRADE  
OF THE CZECH REPUBLIC

## Amendment No. 1 to the framework agreement on the supply of laboratory material

### - Part 10: Reagent chemistry for nucleic acid isolation and library preparation from 2025 to 2026

#### 1. BUYER:

Company name/Name: Institute of Applied Biotechnologies a.s.  
Headquarters: Kramolínská 955, 199 00 Prague 9  
Represented by: RNDr. Petr Kvapil, Chairman of the Board  
Company ID No.: 27225712  
VAT No.: CZ27225712  
Bank details: UniCredit Bank Czech Republic and Slovakia, a.s.  
Account number: 1388101477/2700

The company is registered in the Commercial Register maintained by the Municipal Court in Prague, Section B, Insert 9836.

*(hereinafter referred to as the "Buyer")*

and

#### 2. SELLER:

Business name / Name: QIAGEN GmbH  
Registered office / Place of business: QIAGEN Str. 1; 40724 Hilden, Germany  
Business registration name: QIAGEN GmbH  
ID number: HRB45822  
Represented by: Małgorzata Madjaou  
Entry in the Commercial Register: Handelsregister B im Amtsgericht Düsseldorf  
Bank account: DE16300700100170427900

*(hereinafter referred to as the "Seller")*

*(hereinafter collectively referred to as the "Parties")*

#### Article I – Introductory Provisions

1. The Parties confirm that on 25 August 2025 they entered into the above-specified framework agreement (hereinafter the "Framework Agreement").

#### Article II – Subject of the Amendment

1. The subject of this Amendment is a non-substantial modification of the obligation within the meaning of Section 222(4)(b) of Act No. 134/2016 Coll., on Public Procurement, as amended.



Co-funded by  
the European Union



MINISTRY OF INDUSTRY AND TRADE  
OF THE CZECH REPUBLIC

This modification consists in extending the list of supplied items by additional items that were not part of the original list of tendered items.

2. The change is made due to the need for these items for the purposes of the grant project and the expansion of the laboratory equipment necessary to achieve the established research objectives.
3. The value of these additional items does not exceed 10 % of the original value of the obligation under the Framework Agreement, and the overall nature of the public contract remains unchanged.

### **Article III – Scope of Additional Items**

1. The list of newly added items is set out in the Seller's price quotation, which constitutes Annex No. 1 to this Amendment.
2. All other pricing arrangements, payment, and delivery terms shall be governed by the Framework Agreement.

### **Article IV – Final Provisions**

1. This Amendment constitutes an integral part of the above-mentioned Framework Agreement.
2. All other provisions of the Framework Agreement not expressly affected by this Amendment shall remain unchanged and in full force and effect.
3. The Amendment shall enter into force on the date of signature by the authorized representatives of both Parties and shall become effective on the date of its publication in the Register of Contracts pursuant to Act No. 340/2015 Coll., on the Register of Contracts, as amended.
4. The Amendment is executed in an electronic original.

**Date:**

**Date:** 21 January 2026

**Buyer:**

Institute of Applied Biotechnologies a.s.

**Seller:**

QIAGEN GmbH

**QIAGEN GmbH**

QIAGEN Strasse 1

40724 Hilden

Germany

**Name, Surname, function:**

RNDr. Petr Kvapil,  
Chairman of the Board of Directors

**Name, Surname, function:**

Malgorzata Madjaou  
Tender and Contract Specialist

**Signature:**

.....

**Signature:**

.....

*i. V. J. Madjaou*



Co-funded by  
the European Union



MINISTRY OF INDUSTRY AND TRADE  
OF THE CZECH REPUBLIC

Date: 21 January 2026

**Seller:** QIAGEN GmbH  
QIAGEN GmbH  
40724 Hilden  
Germany

**Name, Surname, function:**  
Michael Hansen  
Senior Manager Sales, Head of ER2i  
Sales EEMEA

**Signature:**

A handwritten signature in black ink, appearing to read "Michael Hansen", is placed over a dotted line.



Veronika Šmotková Kraicová  
Institute of Applied Biotechnologies a.s  
Kramolínská 955  
199 00 Praha

Phone: +420604199153  
Email: smotkova@iabio.eu

20 Jan 2026  
QIAGEN GmbH - a company of QIAGEN Group  
QIAGEN Str. 1  
40724 Hilden  
DE  
Phone: +49-2103-29-0  
Fax: +49-2103-29-21777  
Email: cp-orders@qiagen.com

Quote Number 251209CZ02012131SK  
Customer Number 101492

Dear Veronika Šmotková Kraicová,

Thank you for your interest in our products. Please find below the details of your quotation.

Amendment to the contract:

tender entitled "Supply of Laboratory Supplies - Part 10: Reagent chemistry for nucleic acid isolation and library preparation from 2025 to 2026"

Reference quotation: 250603CZ01938126SK

S No.	Quantity	Catalog #	Product	Unit Price EUR	Total Price EUR
1	1	333074	QIAseq UPX 3' Trans. 12-Index (48)	*831.39	*831.39
2	1	333088	QIAseq UPX 3' Transcriptome Kit (96)	*1,847.14	*1,847.14
3	1	51304	QIAamp DNA Mini Kit (50)	*132.24	*132.24
4	1	51826	QIAamp PowerFecal Pro DNA QIAcube Kit	*1,579.74	*1,579.74

Quote Total Price [EUR]: 4,390.51

\* In case of changes to List Prices at QIAGEN, the prices of these products will remain in effect for the validity period of the quote.

To ensure that correct prices are invoiced please always use the quote number stated above when placing your order.

Goods are delivered subject to the QIAGEN GmbH - a company of QIAGEN Group Terms and conditions of sale which will be sent to you upon request or can be downloaded at <https://www.qiagen.com>

#### Terms of Delivery and payment

Offer validity: Valid From: 09.12.2025  
Valid To: 30.09.2026

Price: Prices do not include VAT

Incoterms: FCA

Payment: Net 30 Days upon Invoicing

This offer was created electronically and is valid without a signature.

#### STATEMENT ON COMPLIANCE WITH EXPORT REGULATIONS

1. QIAGEN is required by applicable sanctions laws to contractually prohibit the re-export of goods to the Russian Federation and Belarus. Therefore, any delivery of QIAGEN products is contingent on the customers commitment to comply with said restrictions.
2. By placing an order for QIAGEN products, you hereby agree not to sell, export or re-export, directly or indirectly, any QIAGEN products to the Russian Federation or Belarus or for use in the Russian Federation or Belarus.
3. Any violation of the obligations stated above shall constitute a material breach of an essential element your purchase agreement with QIAGEN, and QIAGEN shall be entitled to seek appropriate remedies including, but not limited to an immediate termination of the contractual relationship and discontinuation of further deliveries.